Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in EGFR-mutated NSCLC With Meningeal Metastasis
NCT06812871Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), leptomeningeal metastasis (LMD), sponsored by Sun Yat-sen University. Started Jan 2024; status: completed.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LMD)
Beyond the preview
Go deeper on NCT06812871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812871.